Study of Brenipatide for opioid use disorder
Treatments studied
Part of Mental health clinical trials.
This trial tests a new medicine called Brenipatide for people with opioid use disorder who are already taking buprenorphine but still occasionally use non-prescribed opioids. It aims to see if the study drug can help reduce opioid use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a current opioid use disorder that is mild, moderate, or severe.
- You need to be willing to come to all study visits and follow instructions, including self-injecting the study drug or having someone help you.
- You must be using non-prescribed opioids from time to time.
- You must already be taking buprenorphine for your opioid use disorder.
- You cannot have other serious substance use disorders (other than mild alcohol or cannabis, or any tobacco use).
- You must not have had an opioid overdose in the past 6 months, or have certain mental health conditions like schizophrenia or bipolar disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding tirzepatide, a medication used for weight and blood sugar, to buprenorphine treatment helps people with opioid use disorder. It aims to see if the combination improves outcomes compared to buprenorphine alone.
This trial tests a long-acting, once-monthly injection of buprenorphine (BRIXADI) given from a mobile pharmacy clinic. It aims to see if this approach is acceptable and practical for people with opioid use disorder, making treatment more accessible.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This study tests a behavioral support program designed to help people newly starting buprenorphine treatment for opioid use disorder stay engaged with their care. If you've recently started buprenorphine or just been released from incarceration and are beginning treatment, this trial may help you maintain consistent medication use and reduce the risk of relapse.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This trial tests different doses of buprenorphine to find the safest and most effective one for treating opioid use disorder and preventing overdose. It is for people who have used fentanyl and are starting or continuing buprenorphine treatment.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.